Morepen Laboratories Ltd

Morepen Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Morepen Laboratories Ltd

₹ 66.5 2.66%
11 Jun 1:32 p.m.
morepen.com BSE: 500288 NSE: MOREPENLAB
About

Morepen Laboratories Ltd is engaged in the business of manufacturing, producing, developing and marketing a wide range of Active Pharmaceutical Ingredients (APIs), branded and generic formulations and also the Home Health products.[1]

Key Points

Market Leadership
The company is a leader in the pharmaceutical and medical devices industry, holding the top position in 6 APIs with the following market shares as of H1 FY25:
Montelukast (anti-asthmatic): 70%
Loratadine (anti-allergy): 69%
Desloratadine (anti-allergy): 49%
Fexofenadine (anti-allergy): 31%
Atorvastatin (cholesterol reducer): 20%
Rosuvastatin (cholesterol reducer): 19%
Additionally, it is a leader in other products including Sitagliptin, Linagliptin, Dapagliflozin, etc. [1] [2]

Website BSE NSE
  • Market Cap ₹ 3,643 Cr.
  • Current Price ₹ 66.5
  • High / Low ₹ 101 / 41.7
  • Stock P/E 30.9
  • Book Value ₹ 21.1
  • Dividend Yield 0.00 %
  • ROCE 15.1 %
  • ROE 11.8 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.

Cons

  • Stock is trading at 3.16 times its book value
  • Company has a low return on equity of 10.2% over last 3 years.
  • Dividend payout has been low at 3.09% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE SmallCap BSE Allcap

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
368 302 403 348 364 401 422 445 423 455 438 453 466
350 288 374 328 348 375 388 394 375 404 394 417 424
Operating Profit 19 15 29 21 16 26 34 51 48 52 44 36 42
OPM % 5% 5% 7% 6% 4% 7% 8% 11% 11% 11% 10% 8% 9%
3 1 1 1 3 2 3 4 4 3 5 5 5
Interest 1 0 0 1 1 0 0 2 1 1 1 1 5
Depreciation 7 7 7 7 7 8 8 8 10 6 2 5 16
Profit before tax 14 8 22 14 11 21 29 44 42 48 46 35 26
Tax % 13% 32% 29% 36% 26% 29% 26% 27% 32% 25% 24% 24% 21%
12 6 16 9 8 15 21 32 29 36 35 27 20
EPS in Rs 0.26 0.11 0.31 0.18 0.16 0.29 0.42 0.63 0.55 0.71 0.64 0.49 0.37
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
367 401 485 595 607 769 853 1,188 1,547 1,418 1,690 1,812
318 352 424 534 542 701 785 1,070 1,410 1,338 1,532 1,638
Operating Profit 49 48 62 61 65 68 69 119 137 80 159 174
OPM % 13% 12% 13% 10% 11% 9% 8% 10% 9% 6% 9% 10%
4 1 -3 4 4 4 9 12 10 6 14 18
Interest 10 9 10 8 4 2 2 2 -7 2 4 8
Depreciation 46 39 35 34 34 40 37 30 28 28 33 29
Profit before tax -3 2 13 24 30 29 39 99 127 56 135 155
Tax % 0% 6% -1% 0% 0% 1% 14% 1% 20% 31% 29% 24%
-3 2 13 24 30 29 34 97 102 39 97 118
EPS in Rs -0.06 0.05 0.28 0.53 0.66 0.64 0.75 2.16 2.13 0.76 1.88 2.15
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 9%
Compounded Sales Growth
10 Years: 16%
5 Years: 16%
3 Years: 5%
TTM: 7%
Compounded Profit Growth
10 Years: 49%
5 Years: 29%
3 Years: 5%
TTM: 23%
Stock Price CAGR
10 Years: 19%
5 Years: 25%
3 Years: 18%
1 Year: 31%
Return on Equity
10 Years: 13%
5 Years: 14%
3 Years: 10%
Last Year: 12%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 90 90 90 90 90 90 90 90 96 102 102 110
Reserves 88 78 91 106 136 163 194 335 483 651 745 1,047
209 201 187 169 134 132 133 17 19 25 29 105
103 121 156 173 226 230 246 416 473 332 417 517
Total Liabilities 490 489 524 538 586 615 663 858 1,070 1,110 1,293 1,778
368 322 297 272 264 236 216 225 252 267 307 489
CWIP 0 0 0 0 0 0 0 2 14 17 24 28
Investments 0 0 0 0 0 0 1 1 0 0 1 85
121 167 227 266 321 379 446 631 804 827 960 1,176
Total Assets 490 489 524 538 586 615 663 858 1,070 1,110 1,293 1,778

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
34 51 50 41 63 17 11 51 -60 -91 73 32
-1 -32 -27 -14 -27 -13 -12 -70 -32 -47 -83 -322
-29 -19 -27 -24 -38 -0 5 47 66 144 5 300
Net Cash Flow 4 -0 -4 3 -1 4 4 28 -26 6 -5 10

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 42 51 66 57 73 64 59 56 59 68 70 65
Inventory Days 56 55 51 65 76 69 91 82 96 87 85 94
Days Payable 116 126 140 125 173 124 113 98 90 87 101 114
Cash Conversion Cycle -17 -20 -23 -3 -24 9 37 40 65 69 54 45
Working Capital Days -20 -18 -10 -86 -62 -30 -3 22 59 104 99 136
ROCE % 1% 3% 8% 9% 9% 8% 10% 23% 23% 8% 17% 15%

Shareholding Pattern

Numbers in percentages

6 Recently
Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
36.74% 38.22% 38.22% 38.22% 38.22% 38.22% 38.22% 38.22% 38.22% 35.66% 35.66% 35.66%
0.95% 1.15% 0.89% 0.96% 1.00% 1.29% 2.11% 1.85% 1.67% 2.08% 2.22% 1.94%
4.08% 3.98% 3.74% 2.93% 2.32% 2.27% 2.21% 2.15% 2.14% 1.69% 1.64% 1.67%
0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
58.24% 56.63% 57.15% 57.88% 58.45% 58.20% 57.46% 57.76% 57.96% 60.57% 60.46% 60.72%
No. of Shareholders 2,87,1152,90,3673,06,0303,06,1503,01,8323,04,0013,04,2893,36,0193,48,7664,30,9294,48,3614,68,860

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Concalls